BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23182702)

  • 1. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
    Chakravarti A; Wang M; Robins HI; Lautenschlaeger T; Curran WJ; Brachman DG; Schultz CJ; Choucair A; Dolled-Filhart M; Christiansen J; Gustavson M; Molinaro A; Mischel P; Dicker AP; Bredel M; Mehta M
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1206-11. PubMed ID: 23182702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
    Uhm JH; Ballman KV; Wu W; Giannini C; Krauss JC; Buckner JC; James CD; Scheithauer BW; Behrens RJ; Flynn PJ; Schaefer PL; Dakhill SR; Jaeckle KA
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):347-53. PubMed ID: 20510539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
    Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
    Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
    Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
    Colman H; Berkey BA; Maor MH; Groves MD; Schultz CJ; Vermeulen S; Nelson DF; Mehta MP; Yung WK;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):818-24. PubMed ID: 16887285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
    Geyer JR; Stewart CF; Kocak M; Broniscer A; Phillips P; Douglas JG; Blaney SM; Packer RJ; Gururangan S; Banerjee A; Kieran MW; Kun LE; Gilbertson RJ; Boyett JM
    Eur J Cancer; 2010 Dec; 46(18):3287-93. PubMed ID: 20708924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
    Brown N; McBain C; Nash S; Hopkins K; Sanghera P; Saran F; Phillips M; Dungey F; Clifton-Hadley L; Wanek K; Krell D; Jeffries S; Khan I; Smith P; Mulholland P
    PLoS One; 2016; 11(5):e0156369. PubMed ID: 27232884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
    Barker CA; Bishop AJ; Chang M; Beal K; Chan TA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):504-9. PubMed ID: 23523186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
    Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
    J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
    Moyal EC; Laprie A; Delannes M; Poublanc M; Catalaa I; Dalenc F; Berchery D; Sabatier J; Bousquet P; De Porre P; Alaux B; Toulas C
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1396-401. PubMed ID: 17570606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
    Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
    Brown PD; Krishnan S; Sarkaria JN; Wu W; Jaeckle KA; Uhm JH; Geoffroy FJ; Arusell R; Kitange G; Jenkins RB; Kugler JW; Morton RF; Rowland KM; Mischel P; Yong WH; Scheithauer BW; Schiff D; Giannini C; Buckner JC;
    J Clin Oncol; 2008 Dec; 26(34):5603-9. PubMed ID: 18955445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
    Stea B; Falsey R; Kislin K; Patel J; Glanzberg H; Carey S; Ambrad AA; Meuillet EJ; Martinez JD
    Cancer Lett; 2003 Dec; 202(1):43-51. PubMed ID: 14643025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
    Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
    Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.